Lilly Korea to expand presence in lung cancer market

Lilly Korea plans to expand its presence in domestic lung cancer market as the national health insurance has covered ALIMTA (pemetrexed) from this April, following GEMZAR (gemcitabine).

Consistent evidence across the largest body of phase III trials demonstrates that GEMZAR is a leader in the first-line treatment of NSCLC. GEMZAR provides proven strength in survival, time to progression, and...